On September 24, Eli Lilly rose 3.15% in regular trading, trading at $1,187.73 per share with turnover of $455 million. Multiple catalysts converged to drive the stock higher.
On the regulatory front, the FDA approved Eli Lilly's once-weekly basal insulin Onswik for adults with Type 2 diabetes, based on data from the QWINT Phase 3 trials demonstrating non-inferior A1C reduction comparable to daily insulin glargine U-100 and insulin degludec U-100. Onswik can reduce over 300 insulin injections per year, marking the product's fourth global regulatory approval following Europe, Mexico, and Japan. The company plans to launch Onswik in the coming months in two dosage forms.
Separately, Eli Lilly entered a research collaboration and licensing agreement with InnoCare Pharma covering up to five innovative targets. The deal includes up to $100 million in upfront and near-term milestone payments, with total potential development and commercialization milestones of approximately $3.25 billion, plus tiered single-digit royalties on annual net sales.
These developments add to a series of recent strategic moves, including the FDA's expanded cardiovascular indication for Mounjaro, the planned $2.88 billion acquisition of Merida Biosciences, and growing oral GLP-1 market share with Foundayo capturing one-third of new pill patients.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments